Posterior reversible encephalopathy syndrome (PRES) is a neurologic condition characterized by vasogenic edema on neuroimaging and is associated with the setting of severe hypertension, eclampsia, autoimmune disease, malignancy, and immunosuppressive drugs. We report on a 42 year-old female systemic lupus erythematous patient who presented altered consciousness, seizure, and visual disturbance after cyclophosphamide pulse therapy. Magnetic resonance imaging (MRI) showed multi-focal high signal intensity lesions in the parieto-occipital cortex bilaterally and in the subcortical white matter. Her condition was improved and her MRI lesions were resolved after aggressive blood pressure control and high-dose steroid treatment. It is possibly the first reported case of PRES in a patient with lupus, treated with cyclophosphamide pulse therapy during a nephritis flare in Korea.
Introduction
Posterior reversible encephalopathy syndrome (PRES) is a neurologic condition identifiable by characteristic clinical manifestations such as acute headache, altered consciousness, seizure, visual disturbance, and typical magnetic resonance imaging (MRI) features (1). PRES was initially described such as a reversible posterior leukoencephalopathy syndrome (RPLS), reversible posterior cerebral edema syndrome, hyperperfusion encephalopathy and occipital-parietal encephalopathy (1, 2) . RPLS was a term initially coined by Hinchey et al. when these investigators described 15 patients treated with a reversible syndrome characterized by an acute or subacute onset of altered mental status, headache, seizure, and/or loss of vision associated with white matter changes, mostly in a bilateral parieto-occipital distribution on a MRI (1) . These patients had different underlying conditions such as eclampsia, immunosuppressive therapy, organ transplantation, hypertensive encephalopathy and systemic lupus erythematosus (SLE) (1) . Then, it has been suggested that PRES does not implicate a single disease, although the symptoms, signs, and neuroradiologic findings related to PRES do not markedly differ (2) .
It can present as a neurological emergency and may lead to permanent brain injury and sequelae without prompt treatment, but with prompt treatment almost always resolves within 2 or 3 weeks. PRES is mainly caused by hypertensive encephalopathy, eclampsia, autoimmune disease, and some immunosuppressive therapies. However, PRES after a cyclophosphamide pulse in a patient with SLE has not been reported in Korea. We describe a patient with SLE on cyclophosphamide therapy that developed acute neurologic changes initially suggesting cerebritis or stroke. These findings were subsequently found to be secondary to PRES. We also discuss the contributing factor, treatment and therapeutic implications for separating PRES from stroke and cerebritis in this report.
Case Report
A 45-year-old woman presented with malaise, fatigue and Severe hypertension and renal failure are known risk factors for the development of PRES (1). However, in our case, we found that severe hypertension is not an invariable association, indicating that it may not be in the extended spectrum of hypertensive encephalopathy that may be seen in SLE with renal involvement. It is interesting that case reports of PRES in normotensive patients with SLE were ascribed to high doses of corticosteroids (1, 8) or to cytotoxic therapy with cyclophosphamide (CYC) (9) . Occurrence of PRES in normotensives and treatment-naïve patients may explain the endothelial dysfunction due to disease activity playing an important pathogenic role (10).
Our patient was normotensive and receiving 2 cyclic CYC and intermediate dose of corticosteroids when she developed PRES. The use of immunosuppressants is considered one of the risk factors; cyclosporine is one of the most common immunosuppressants associated with PRES and is well studied (11) . The mechanism is thought to be mediated through mitochondrial dysfunction (12) . High dose of corticosteroids are implicated in the occurrence of PRES by predisposing a patient to hypertension and fluid overload (13) . The mechanism of CYC that predisposes a patient to PRES is not clearly known. It can cause water toxicity in the first 2 days after infusion due to an unknown action on renal function that is not explained by the antidiuretic hormone; a similar role may be implicated in PRES in our patient who developed it 2 days after infusion (14) . We could not find schistocyte in patient's PBS, then could exclude the possibility of thrombotic thrombocytopenic purpura.
Up to date, very few cases of PRES in patients treated with combination chemotherapy including cyclophosphamide, prednisone, vincristine and adriamycine have been reported and other cases with the combination of hydroxy-chloroquine, steroids and cyclophosphamide or adriamycine, cytarabine have been published as well, but in all cases the authors could not determinate which drug (or combination) was the cause (15).
In our case, we could not conclude whether cyclophosphamide was the cause of PRES, but it was most likely because our patient recovered from nephritis flare up, had low disease activity scores if seizure was considered to be caused by PRES and was received with intermediate dose of steroid, and her blood pressure was normotensive.
Renal failure with a state of fluid overload is a well-known cause for PRES (1) . In the literature review by Leroux et al, 91% of patients had renal involvement, with renal insufficiency in 84% of the cases (6). However, the fact that only one in 13 patients had renal failure in another study emphasizes that disease activity rather than fluid overload could be responsible for the occurrence of PRES.
In a previous study, the relationship between PRES and the presence of antiphospholipid antibodiesis difficult to assess.
However, 12 of 17 cases tested positive for anticardiolipin antibodies (11), in comparison to 2 of 8 in another study (4) .
There is need for further study to fully describe the relationship between antiphospholipid antibodies and PRES. In our case, antiphospholipid antibodies of the patient were negative. Although the general recommendation is to withdraw the offending drug, after control of the acute episode was achieved, but patients had no recurrences with reuse of CYC on follow-up (4). This reiterates that multiple etiologies may be responsible for the occurrence of PRES in SLE patients already undergoing treatment with cytotoxic therapy.
PRES is considered benign and a complete recovery can be expected, but residual deficits are not uncommon, as noted in previous reports, which can include hemiparesis and death (3, 4) , then prompt diagnosis and treatment should be done.
PRES occurs in young patients with lupus, especially in the early stages of the disease. Many immunosuppressive drugs are implicated with this syndrome, associated with arterial hypertension in almost all cases. Cyclophosphamide is one of the most widely used immunosuppressive drugs in SLE, with many well described secondary effects, and posterior reversible leukoencephalopathy syndrome could be one of them.
Management is predominantly symptomatic treatment. Early diagnosis and management is productive. Without any evidence of infections or severe hypertension, cyclophosphamide might well be considered one of the causes of PRES.
